Immunohistochemical Evaluation of Epidermal Growth Factor Receptor (EGFR), MMP-2 and Heparanase in Pleomorphic Adenoma of Salivary Glands
Abstract
Background: Salivary gland tumors are morphologically and clinically diverse group of neoplasms .The most common benign tumor
is the pleomorphic adenoma, it contains the epithelial, myoepithelial and mesenchymal component, with variable morphological
patterns. Epidermal growth factor receptor (EGFR) is a 170 KD glycoprotein which has a tyrosine kinase activity. It is found at
abnormally high levels on the surface of many types of cells, so these cells may divide excessively in the presence of epidermal
growth factor.MMP-2 is a widely studied matrix metalloproteinase which participates in extracellular matrix (ECM) degradation,
having a wide range of substrates and able to degrade type I, IV, V, VII and X collagens, laminin, elastin, fibronectin and proteoglycans.
Heparanase (HPA) is an endo-β-D-glucuronidase that has the activity of cleaving heparan sulfate (HS) side chains of heparan sulfate
proteoglycans (HSPGs), the major proteoglycans of the extracellular matrix (ECM) and basement membrane (BM) which play a key
role in preventing tumor cells invasion and metastasis.
Aims of the study: This study aimed to evaluate the expression of EGFR, MMP-2 and heparanase in pleomorphic adenoma of
salivary glands and to correlate the expression of the aforementioned biomarkers with the clinical parameters, histological subtypes
and components, and with each other as well.
Materials and methods: Twenty five paraffin blocks of pleomorphic adenoma were included in this study. Sections
immunohistochemically stained with anti EGFR, anti MMP-2 and anti heparanase monoclonal antibodies (Mabs).
Results: Positive EGFR, MMP-2 and hepranase immunohistochemical expression was found in 22 (88%), 14(56%) and 21 (84%) of
the studied cases respectively. Statistically non- significant correlation was found among the aforementioned markers with each
other, and between the markers and any of the clinical parameters and histological classifications, except a statistically highly
significant negative correlation revealed regarding EGFR expression with the squamous cells of epithelial component (p =0.001)
and a highly significant positive correlation found regarding MMP-2 expression with the chondroid stromal component (0.003).
Conclusions: Histological variation of pleomorphic adenoma has no influence on its biological behavior concerning EGFR, MMP-2
and heparanase expression. The immunoscores reorded in this study are expected to contribute to a better understanding of the
biological behavior of PA.
References
Ellis GL, Auclair PL.Tumors of salivary glands (Atlas
of tumor pathology) 3rd series.Fascies .Fascicle 17.
Washington, DC; Armed forces of institute of pathology;
Stennert E, Guntinas-Lichius O, Klussmann JP, Arnold
G . Histopathology of pleomorphic adenoma in the
parotid gland: prospective unselected series of 100 cases.
Laryngoscope 2001; 111(12) : 2195-2200.
Ito FA, Jorge J, VargasPA, Lopes MA. Histopathological
findings of pleomorphic adenomas of the salivary glands.
Med Oral Patol Oral Cir Bucal. 2009; 14 (2): 57-61
Downward J, Parker P, Waterfield MD “Autophosphorylation
sites on the epidermal growth factor receptor”. Nature
; 311 (5985): 483–5.
Furuse C, Miguita L, Rosa AC, Soares AB, Martinez
EF, Altemani A, de Araújo VC. Study of growth factors and
receptors in carcinoma ex pleomorphic adenoma. J Oral
Pathol Med .2010; 39(7):540-7.
Ozanne, B., Richards, C.S., Hendler, F., Burns, 0. &Gusterson
B. Over-expression of the EGF receptor is a hallmark of
squamous cell carcinomas. J. Pathol. 1986; 149: 9.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM.J
Clin Oncol. Matrix metalloproteinases: biologic activity
and clinical implications.2000; 18(5):1135-49.
Egeblad M, Werb Z. New functions for the matrix
metalloproteinases in cancer progression. Nat 2002;
(3):161-74.
Cawston TE, Wilson AJ. Understanding the role of tissue
degrading enzymes and their inhibitors in development and
disease. Best 2006; 20(5):983-1002.
Page-McCaw A, Ewald AJ, Werb Z. Matrix
metalloproteinases and the regulation of tissue remodelling.
Nat Rev Mol Cell Biol. 2007 Mar; 8(3):221-33.
Clark IM, Swingler TE, Sampieri CL, Edwards DR. The
regulation of matrix metalloproteinases and their inhibitors.
Int J Biochem Cell Biol. 2008; 40(6-7):1362-78.
Mott JD and Werb Z.Regulation of matrix biology by matrix
metalloproteinases Curr Opin Cell Biol. 2004; 16(5): 558–
Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt
HJ, Hristic M, Berclaz G, Ziemiecki A, Andres AC. Tumor
cell specific expression of MMP-2 correlates with tumor
vascularisation in breast cancer.Int J Oncol. 2002 Jul;
(1):25-30.
Vihinen P and Kähäri V. Matrix metalloproteinases in
cancer: Prognostic markers and therapeutic targets .INT.J
Canc .2002. ; 99 (2): 157–166
Chambers AF and Matrisian LM. Changing views of the
role of matrix metalloproteinases in metastasis. . J. Natl.
Cancer Inst. 1997; (89):1260-1270.
DeClerck YA, Imren S, Montgomery AM, Mueller
BM, Reisfeld RA, Laug WE. Proteases and protease
inhibitors in tumor progression.Adv Exp Med Biol. 1997;
:89-97.
Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon
R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal
I, Spector L, Pecker I . “Mammalian heparanase: gene
cloning, expression and function in tumor progression and
metastasis”. Nature Medicine .1999; 5 (7): 793–802.
Vlodavsky I, Goldshmidt O, Zcharia E et al. “Mammalian
heparanase: involvement in cancer metastasis, angiogenesis
and normal development”. Semin. Cancer Biol. (2003).
(2): 121–9.
Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi
A, Torri G, Casu B, Sasisekharan R. Heparanase, heparin
and the coagulation system in cancer progression.Thromb
Res. 2007; 120 Suppl 2:S112-20.
Neta Ilan, Michael Elkin, Israel Vlodavsky. Regulation,
function and clinical significance of heparanase in cancer
metastasis and angiogenesis.The_International_Journal_
of_Biochemistry and_Cell_Biology (2006); 38 (12), 2018-
Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold
C, Ostertag H, Roessner A Expression of matrix
metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin
B, and urokinase plasminogen activator in non-skull base
chordoma. .Am J Clin Pathol. 2004 Dec;122(6):926-30.
Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong
D, Barbieri V, Jank S, Doppler W, Rasse M, Norer B.
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and
oropharynx: a TMA-based immunohistochemical analysis.
Oral Oncol. 2007 Feb;43(2):193-8.
Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner
A, Nielsen S, Ilan N, Vlodavsky I, Reich R. Heparanase
and basic fibroblast growth factor are co-expressed in
malignant mesothelioma. Clin Exp Metastasis. 2004;
(5):469-76.
Takeda Y.An immunohistochemical study of bizarre
neoplastic cells in pleomorphic adenoma: its cytological
nature and proliferative activity, Pathol Int, 1999; 49; 993-
Cardesa A, Slootweg P.J.: Pathology of the Head and Neck;
Major and minor salivary glands. Springer-Verlag Berlin
Heidelberg, 2006; 5:137-147.
Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S,
Vlodavsky I, and Nagler R. Heparanase Expression in
Malignant Salivary Gland Tumors Inversely Correlates
with Long-Term Survival. Neoplasia. 2006 ; 8(10): 879–
Ettl T, Schwarz S, Kleinsasser N, Hartmann A, T E Reichert
& Drieme O. Overexpression of EGFR and absence of
C-KIT expression correlate with poor prognosis in salivary
gland carcinomas.Histopathology 2008, 53, 567–577.
Lipari L, Mauro A, Speciale R, Gerbino A, Buscemi
M. Expression of remodelling enzymes (MMP2, MMP9)
in samples of salivary gland’s tumors. IJAE. 2010; 115, (
/2) (Supplement),
Eveson JW and Cawson RA .Salivary gland tumors .A review
of 2410 cases with particular references to histological
types ,site age and sex distribution .J Pathol,1986 ;146 :51-
ChidzongaMM ,Lopes peresVM ,Portilla Alvarez AL.
Pleomorphic adenoma of salivary glands .Clinicopathologic
study of 206 cases in Zimbabwi.Oral Surg,Oral Med,Oral
Pathol,Oral Radiol Endod ,1995;79:747-9
Williams NP,Boyd DL,Choy L,Hanchard B.Salivary
gland lesions :a Jamaican prospective.West Indian Med
J,2001;50:62-5
Takahama A Jr, DaCrus Perez DE ,Magrin J ,.DE Almeida
OP,Kowalski LP.Giant pleomorphic adenoma of the parotid
gland .Med Oral Patol Oral Cir Bucal ,2008;13 E58-60.
Ledesma-Montest C,Garces-Ortiz M.Salivary gland tumors
in a Mexican sample.Aretrospective study.Med Oral
,2002;7:324-30
Paris J,Facon F,Chrestian MA ,Giovanni A,Zanaret
M.Pleomorphic adenoma of the parotid gland
:histopathological study ,Ann Otolaryngol Chir
Cervicofac,2004 ;121:161-6.
Kusafouka K,Luyten FP,De Bondt R ,Hiraki
Y,ShukunamiC,Kayano T,et al ,Immunohistochemical
evaluation of cartilage-derived morphogenic protein -1
and 2 in normal human salivary glands and pleomorphic
adenomas.Virchows Arch.2003;442:482-90
Ohtake S,Cheng J,Ida H ,Suzuki M,Ohshiro K,Zhang W,et
al .Precancerous foci in pleomorphic adenoma the salivary
glands:recognition of focal carcinoma,and atypical tumor
cells by P53 immunohistochemistry .J Oral Pathol Med
,2002 ;31 :590-7.
Kusafuka K, ,Hiraki Y,ShukunamiC, Yamaguchi A
,Kayano Takemra T .Cartilage –specific matrix protein
chondromodulin -1 is associated with chondroid formation
in salivary pleomorphic adenomas:immunohistochemical
analysis.Am J Pathol.2001;158:1465-72.
Zheng L, Fan Z, He S. A study on expression of epidermal
growth factor receptor in pleomorphic adenoma of lacrimal
gland. Zhonghua Yan Ke Za Zhi. 1995 May;31(3):212-4.
Yamada K, Iwai K, Okada Y, Mori M. Immunohistochemical
expression of epidermal growth factor receptor in
salivary gland tumours. Virchows Arch A Pathol Anat
Histopathol. 1989;415(6):523-31.
AL-Rawi NH, Al-Samarai M, Al-Kawas S, Majeed AH.
Expression of matrix metalloproteinase - MMP-2 and
tissue inhibitor TIMP-2 in intra oral pleomorphic adenoma
and adenoid cystic carcinoma . J Int Dent Med Res 2011;
: (1), pp. 1-6 .
The Expression of Matrix Metalloproteinases and Tissue
Inhibitors of Metalloproteinase in Salivary Gland Tumors.
Posted on June 20, 2010 by China Papers.
LuYann .The Expression of Matrix Metalloproteinase-2 and
Endoglin in Salivary Gland Tumors.Master thesis(2010)
Pepper MS .Role of the Matrix Metalloproteinase and
Plasminogen Activator–Plasmin Systems in Angiogenesis
. Arterioscler , Thromb Vasc Biol .2001; 21: 1104-1117
Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky
I, and Ilan N Heparanase augments EGF-receptor
phosphorylation: correlation with head & neck tumor
progression. Cancer Res. 2008 15; 68(24): 10077–10085.
Sternlicht MD and Werb Z.How Matrix Metalloproteinases
Regulate Cell Behavior.Annu Rev Cell Dev Biol
.2001;17:483-518.
DOI: http://dx.doi.org/10.26477/idj.v36i3.23
Refbacks
- There are currently no refbacks.
--------------------------------------------------------------------------------------------
ISSN (Print): 2307-4779 | ISSN (Online): 2411-9741